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Summary Radioimmunotherapy (RIT) is currently limited by toxicity to normal tissues as a result of prolonged circulating radioantibody in the
blood. In this study, the use of a cleanng antibody was investigated (second antibody) in an attempt to reduce blood background levels of
[9Y]A5B7 immunoglobulin G (IgG) activity, and, therefore, improve the therapeutic tumour-blood ratio in nude mice bearing human colorectal
tumour xenografts. The second antibody was raised against the 12N4 macrocycle group used for chelation of 90Y. and is, thus, applicable to
any anti-tumour antibody labelled with this methodology. Second antibody was administered 18, 24 or 48 h after radiolabelled antibody
injection and produced up to a tenfold reduction in blood levels and a tenfold improvement in tumour-blood ratios. This has the advantage of
reducing the risk of myelotoxicity caused by prolonged retention of activity in the blood. For all normal tissues, there was a similar or slightly
lower uptake of [90Y]lgG with second antibody clearance, apart from a transient rise in liver activity due to complexes of primary and
secondary antibody clearing via the liver. As a result of clearance of [90Y]lgG from the blood pool, there was an associated fall in the amount
of antibody at the tumour site (up to 3.3-fold) at later time points for mice injected with second antibody. However, despite this, tumour-blood
ratios remained superior to the control group at these later time points. Estimated dosimetry evaluation revealed that total dose to normal
tissues, blood and tumour was lower than for the non-clearance group. Surprisingly, however, there was little improvement in total estimated
tumour-blood dose ratio over the time period studied. This was probably because the majority of the dose was delivered to both the blood and
tumour within the first 24 h after administration of [90Y]lgG, so that giving the clearing agent after this time did not produce a large difference
in total estimated dose. The anti-macrocycle second antibody proved to be a successful clearing agent and could potentially be applied to any
anti-tumour antibody coupled with the 12N4 macrocycle. In the light of the estimated dosimetry results described here, it would probably be
most useful given at earlier time points (i.e. before 18 h after injection of primary antibody) to produce an improved tumour-blood ratio of total
dose. Development of this strategy may allow higher levels of activity to be administered for RIT, and repeated dosing regimens.
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Effecti-e radioimmunotherapy (RIT) requires delixerx- of a lethal
dose of radiation to the tumour xxith minimal darnage to normal
tissues. The slow clearance of intact radiolabelled antibodies from
the circulation and the time necessarv to achieve maximum uptake
by the tumour has often resulted in large radiation doses to normal
tissues. The amount of radiation that mav be administered for RIT
is often limited by the potential damage to normal tissues. espe-
cially the bone marrow. caused by the persistence of radiolabelled
antibodv in the circulation. Sexeral strategies hax-e been employed
in an attempt to remove circulating antibody more rapidly. and
produce high tumour-blood (therapeutic) ratios. These include the
use of smaller. faster. clearing antibody fragments (Buchegger et
al. 1990: Pedley et al. 1993). and specific in x-ivo or ex vivo
clearing regimes (Begent et al. 1987: Norrgren et al. 1993).
Prev-ious studies haxe demonstrated successful implementation of
clearing acents. The use of a second antibody directed against the
(pnmary) anti-tumour antibody has accelerated clearance and
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improved therapeutic ratios (Begent et al. 1987: Pedley et al.
1989). Other strategies have involved liposomally entrapped
second antibodies (Keep et al. 1983) and axvidin-biotin systems
(Marshall et al. 1995).
Most therapeutic studies to date haxe been carried out using the
radionuclide iodine-131 (1""I). xhich is a medium range 3-emitter
(0.6 MeV). However. there are problems associated with handlin2
large doses of ""I for RIT because of the high abundance of y-
energy. More recently. sex eral inxestigators have suggested that
alternative radionuclides such as yttrium-90 COY) or copper-67
C6-Cu) may be superior to ""I for RIT (Deshpande et al. 1988:
King et al. 1994). Faxourable characteristics include higher -
energy. shorter physical half-lives and stable chelation methods.
Several studies hax e also reported higher tumour uptake and
prolonged retention of5'Y in tumour cells compared with I'l. e.g.
Press et al (1996).
The murine antibodv A5B7. raised against carcinoembrxonic
antigen (CEA). has been used for RIT labelled w-ith "I in nude
mice bearing human colorectal tumour xenografts (Pedley et al.
1993) and in patients with colorectal cancer (Lane et al. 1994).
Good therapeutic responses haxe been demonstrated in xenograft
models. but only a small number ofresponses hax e been produced
clinicallI. In a recent studv. the 12N4 DOTA macrocvcle was
conjugyated to A5B7 IgG and sucessfully radiolabelled wxith 41Y.
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The biodistribution of A5B7 IgG radiolabelled %vith either '"'I or
9'Y in the nude mouse xenograft model was compared and the
results showed that higher tumour uptake and retention of
[3VY]IgG was observed (Casey et al. 1996). The aim in this studv
was to investigate whether tumour-blood ratios could be further
improved for [VY]IgG using a second antibody clearance system
based on an antibodv raised against the 12N4 DOTA macrocycle.
MATERIALS AND METHODS
Antibodies
The 12N4 DOTA macrocvcle %vas conjugated to bovine serum
albumin for immunizations. usinc the method previouslI
described by Turner et al ( 1994). The mouse IgG1 anti-macrocycle
antibody (1C) C -as raised using conventional hybridoma tech-
niques and shown to be specific for the 12N4 macrocycle (Chaplin
et al. in preparation). The mouse IgG1 anti-CEA antibody A5B7
was conjucated to the 12N4 macrocyvcle group for 'Y labelling, as
described previously (Casev et al. 1996).
Biodistribution experiments
A5B7 IgG was radiolabelled A-ith +'Y to a specific activity of
74 kBq g1-'. purified by high-performance liquid chromatography
(HPLC) grel filtration and characterized as descnrbed previously
(Casey et al. 1996). All the MF1 nude mice bearing LS174T
human colorectal carcinoma xenografts (Pedlev et al. 1993) were
injected by the tail v-ein intravenously (i.s-.) w-ith approximately
10 MBq of [90Y]IgG. Test animals s-ere subsequently injected
intraperitoneally (i.p.) swith clearing antibody 1C2 at a fivefold
molar excess (approximately 25 pa) oser the amount of labelled
antibody oriainallv administered. Clearing was tested at 18. 24 or
48 h after injection of radiolabelled antibody. Test and control
animals %vere bled and tissues removed for radioactivity assess-
ment at various time inters als after injection. Bremstrahlunr
radiation from 4`Y in tissues was counted using a calibrated
camma-counter (WNizard. Wallac. UK). The Mann-Whitnev non-
parametric statistical test was used to compare data and results
were considered to be sienificant w-hen P < 0.05.
Dosimetry
Estimated radiation doses (,) to blood. tumour and normal tissues
per MBq of `Y injected were evaluated from the biodistribution
data. Figures for percentage of injected actisity per gram of tissue
(%c ia g-l) were decay corrected and the area under the %7 ia o-'
over time curse w'as calculated using, the trapezoidal rule. Total
estimated 0 dose to indi-idual tissues was assessed using the
MIRD S factor of 1.93 for 90Y (MIRD pamphlet 11. 1975) to
convert MBq c-' to cGy h-'. There A-as no correction for cross-
organ doses.
RESULTS
To assess whether the anti-macrocycle clearing antibody (1 C2)
could complex and clear 4'Y-labelled A5B7 IgG from the blood
pool. a fivefold molar excess of unlabelled 1C2 was administered
at various time points after radiolabelled antibody injection.
Previous experiments hase show-n that this level of second anti-
body in similar clearance systems was optimal: lower doses did
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Figure 1 Biodistribution of [wY)A5B7 IgG (control) with and without second
antibody clearance with 1C2. in nude mice bearing LS174T human tumour
xenografts. (A) 25-h time point for control and 1 h after administration of 1C2
(24-h clearance group); (B) 49-h time point for control, 24 h (24-h clearance
group) and 1 h (48-h clearance group) after administrabon of 1C2; (C) 121-h
time point for control, 96 h (24-h clearance group) and 72 h (48-h clearance
group) after administration of 1C2. Results are expressed as a percentage of
injected actvity per gram of tissue, columns are means of four mice and bars
represent standard deviatbons
British Joumal of Cancer (1998) 78(10). 1307-1312
A
E
a
CL
.4
a
B
. CancerResearch Campaign 1998
Mcowd
01 hdeararmAntibody clearance with anti-macrocycle antibodies 1309
Table 1 Tumour to blood rabos of [9YIA5B7 IgG in nude mice bearing
LS174T human colorectal tumour xenografts, with and without second
antibody administered 24 h and 48 h after radiolabelled antibody injection.
NB. Control group time points were increased by 1 h to 25 h, 49 h and 121 h
Tumour-blood ratios
Control 24-h clearance 48-h clearance
24 h 2.15 22.8 -
48 h 5.97 41.2 42.5
120 h 10.4 15.1 32.7
not produce the desired effect and there x as no significant
improvement at higher doses (Pedlev et al. 1989).
24- and 48-h clearance
The clearing antibodyxxas initiallv administered 24 h and 48 h after
injection of4'Y-labelled IgG. and the biodistribution was compared
with the control group with no clearing antibody (FFigure 1).
Administration of 1C2. 24 h after injection of [9''Y]IgG.
produced a rapid decrease in the level of labelled antibodx in the
circulation (Figure 1A). By 1 hour after injection (25 h post anti-
tumour antibody). the clearing, antibody had produced a significant
reduction (9.7-fold) in blood radioactivitv level from 9.5% to
0.98%- ia o-' (P < 0.05). This was accompanied by a large rise
(fourfold) in liver activitv from 4.8%c to 19.0%7 ia a-' (P < 0.05)
probably due to complexes of primary and secondary antibody
clearingc via the liver. At later time points. 24 and 96 h after admin-
istration ofclearing antibody (Figure IB andC.) there was an asso-
ciated ninefold and 4.7-fold reduction in blood activitv.
respectively. compared with control animals (P < 0.05). Although
liver activitv levels were hicher than for the control group at these
later time points (1.8-fold and 1.42-fold respectively). the differ-
ence was not siganificant. For all normal tissues. there was similar
or slightly lower uptake of [9"Y]IgG with second antibody clear-
ance. in particular there was reduced splenic (6.0% reducing
to 2.8% ia ca-' 24 h after clearance) and luna activitv (4.4%7 to
1.5% ia 24 h after clearance). The amount of radioactivitv
retained in the tumour was not significantly different 1 h and 24 h
afterclearance. but at a later time (96 h afterclearance) there was a
large decrease in tumour activity (26%7 to 8.0% ia g-1). The large
reduction in circulatina antibody after injection of clearinc anti-
bodv and similar retention of activity in the tumour to the control
grroup (to 48 h) produced up to a tenfold improvement in thera-
peutic tumour to blood ratios (Table 1).
Clearance at 48 h produced a similar effect. whereby activity in
the blood fell sharply by a factor of 8 (P < 0.05) within 1 hour of
injection (5.5%7 to0.69%7 iagl-'). Aaain liver activitv was increased
1.7-fold. but this was less dramatic than forclearance at 24 h (four-
fold). Normal tissue clearance was similar to the 24 h clearance
group as described above. There was no significant difference in
tumour activity when compared with either the control or the 24-h
clearance group by 1 h after clearance. However. again at the latest
time point (72 h after clearance) tumour levels fell from 26%7 to
11.1% ia g Tumour-blood ratios were significantly improved
(7.1-fold) 1 h after clearance. Although tumour activitv was
reduced at the later time point ( 120 h). the accompanied reduction
in blood levels still created a 3.3-fold increase in tumour-blood
ratio (33:1 compared A-ith 10:1 for the control group).
Table 2 Tissue doses of F-radiation (cGy/MBq injected dose) calculated
from the area under the curve using the trapezoidal rule from the
biodistributon data in Figure 1. Figures were corrected for radioactive decay
Tissue Control 24-h clearance 48-h clearance
Blood 636 374 488
Liver 272 562 648
Kidney 104 69.6 74.0
Lung 167 66.2 66.6
Spleen 205 122 133
Colon 53.7 37.4 34.4
Muscle 41.4 34.0 31.8
Femur 57.4 64.4 70.0
Tumour 1191 747 910
Total 2728 2077 2456
Tumour-blood ratio 1.87 2.0 1.87
Tumour-liver ratio 4.38 1.33 1.40
Table 2 shox s the estimated radiation dose to tumour and
normal tissues per MBq of 4'Y administered for animals xxith and
without second antibody clearance. Use of clearance antibody.
civ-en either at 24 or 48 h. reduced the total radiation dose received
by all organs. except the lixer. This included a 1.7-fold and 1.3-
fold reduction in blood dose for 24 and 48 h clearance groups
respectively. The increase in liv-er activity at all time points in both
clearing groups produced a tuxo- to 2.4-fold higher estimated total
dose than for the control group. There wvas an associated decrease
in dose delivered to the tumour when the second antibodvx as
given (1.6- and 1.3-fold for 24 and 48 h clearance groups respec-
tively). In spite of improved tumour-blood ratios at each time
point shoxxrn in Table 1. the oxerall tumour-blood ratios of total
estimated dose were surprisingly similar to the non-clearance
group (Table 2). The beneficial effect ofsecond antibody clearance
was obserxed within the first 24 h after administration of clearinr
agent wxhich resulted in a tenfold decrease in total dose to blood
during this period (data not shox-n). However. because the largest
dose delivered to both the blood and tumour occurred within the
first 24 h after administration of[VY]IgG and because the clearinc
agentwxas gix en after this time. a large difference in total estimated
dose was not produced.
18-h clearance
Further experiments were performed to inxestigate the effect of
earlier clearance (before 24 h) and to cain more information on the
first 24 h of [90Y]IgG administration. Ficure 2A illustrates a more
detailed examination of the biodistribution of [9°Y]IgG (without
clearance) to 72 h. Activitv localized to the tumour. and by 18 h
there were higher levels of activity in the tumour than blood and
all other normal tissues. Tumour activity accumulated over time
duringr the 72-h period while radiolabelled antibody cleared from
the blood. After this time. the actix itx in the tumour begyan to fall
(Ficure 2C). Other normal tissues. wxith the exception of liver and
spleen. showed a similar pattern of clearance related to the blood
pool activitv.
Clearance at 18 h produced a significant decrease (P < 0.05) in
blood activity (6.2- and 6.6-fold) measured 24 and 48 h afteradmin-
istration (Figure 2B and C). In contrast to administration ofclearinc
agent at 24 h (Figure 1). tumour uptake lexels were significantl1
British Joumal ofCancer (1998) 78(10). 1307-1312 0 CancerResearch Campaign 19981310 JL Caseyetal
A
E
10
0 Is
10
0
S
B
C
a.
B
E
IS.
0.
.5 Zs Z
is
S
S0
a
C S 2
S
0.
C
E
cmc
0.
o
0
2D-
0.
C
I
0 0 -5
0 4>0
C 0 -a E 0 0n
- 1 -1 '& 0 E 2 co 2 9~~~~~I
Figure 2 Biodistribution of [9cY-A5B7 IgG (control) with and without second
antibody clearance with 1C2, in nude mice bearing LS174T human tumour
xenografts. (A) Control biodistribution at 3 h (first column), 6 h (second
column), 18 h (third column), 24 h (fourth column), 48 h (fifth column) and
72 h (sixth column) after i.v. injection; (B) 48-h time point for control group
and 24 h (18-h clearace group) after administration of 1C2; (C) 72-h time
point for control group and 48 h (18-h clearance group) afteradministration of
1C2. Results are expressed as a percentage of injected actvity per gram of
tissue, columns are means of four mice and bars represent standard
deviations
Table 3 Tumour-blood ratios of [cY]A5B7 IgG in nude mice bearing
LS174T human colorectal tumour xenografts. with and without second
antibody administered 18 h after radiobabelled antibody injecton
Tumour-blood ratios
Control 18-h clearance
3h 0.36 -
6 h 0.71 -
18h 2.50 -
24h 3.55 -
48 h 5.22 17.0
72 h 8.65 23.4
Table 4 Estimated tissue doses of F-radiation (cGy/MBq injected dose)
calculated from the area under the curve using the trapezoidal rule from the
biodistribufon data in Figure 2
Tissue Control 18-h clearance
Blood 396 247
Liver 466 562
Kidney 205 48.8
Lung 168 111
Spleen 239 184
Colon 59.2 45.5
Muscle 38.1 37.7
Femur 91.8 98.4
Tumour 932 614
Total 2595 1948
Tumour-blood ratio 2.35 2.49
Tumour-liver ratio 2.00 1.09
reduced (P < 0.05) from 36% ia g-- to 18.7%7c ia g-' within 24 h of
injection of clearing agent (Figure 2B). By 48 h after clearance.
there was a more marked difference in tumour activity. 18%c ia g'l
remained in the tumour compared with 44%7c ia g-' of the control
group (P < 0.05). However. in spite of this. because of the large
reduction in blood activity. there was a large improvement (up to
3.3-fold) in tumour-blood ratios at both these time points on addi-
tion ofclearing antibody (Table 3). Similarly. at the later time points
there was a reduction in activity for all tissues. except the liver and
femur. for the clearance group compared with control animals. It
was predicted that levels ofactivity in the liver wouldrise in the first
few hours following injection ofclearing agent. as seen with the 24-
h clearance group. but it must be noted that this time point was not
included in the biodistribution and dosimetry evaluations (1 h after
injection ofclearing agent). By 24 h after clearance. there was only
a small rise in liver activity from 12%c to 16%7 ia g which was not
significantly different to the control group.
Estimated total doses were evaluated over the 72-h period with
and without administration of clearing agent 18 h after injection
(Table 4). Again. there was a reduction in total absorbed dose to
normal tissues. blood and tumour for the clearance group.
However. despite the 1.6-fold reduction in blood dose tumour
levels were also 1.5-fold lower. which did not improve the overall
tumour-blood ratios (2.49:1 as opposed to 2.35:1 for the control
group). Absorbed dose to the liver was also 1.2-fold higher. which
produced a lower tumour-liver ratio.
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DISCUSSION
In this studv. the first use ofthe anti-12N4 DOTA macrocvcle anti-
body (1C2) as an in vi-xo clearing agent is described. The most
frequently reported dose-limiting toxicity in clinical RIT studies is
myelosuppression (Bernstein et al. 1991: Lane et al. 1994). It has
been established that a large part of the dose to bone marrow is
delivered through high levels of circulating activity in the blood.
Therefore. if a reduction in blood levels ofactivity can be achieved
usinc a clearing antibody. it would be expected that myelosuppres-
sion could be reduced. and larger doses could then be given with
the prospect ofpotentially achieving higher doses to the tumour.
The biodistribution studies showed a substantial reduction in the
level of [90Y]IgG in blood and normal tissues after the cleanrng
antibody was given. although there was a transient rise in radio-
activity in the liver due to rapid clearance of immune complexes
via that organ. Most of the activity was cleared from the liver
within 24 h of administration of clearing antibody. There was no
associated increase in splenic activity using this clearino agent.
which is an obvious advantage over the use of other second anti-
bodies or clearing strategies which have demonstrated high accu-
mulation of activity in the spleen (Pedley al. 1989: Goldenberg et
al. 1987: Marshall et al. 1994). The spleen also catabolizes radio-
labelled antibody complexes at a much slower rate and is more
radiosensitive than the liver. which is disadvantageous in terms of
an increased total and cross-organ absorbed dose.
Accelerated clearance of primary antibody produced higher
tumour-blood ratios (up to tenfold). but unfortunately the levels of
activity associated with the tumours of animals receiving second
antibody were significantly lower at later time points. This is a
common finding with most if not all other clearing systems and.
unfortunately. appears to be unavoidable (Sharkey et al. 1988:
Pedley et al. 1989). Ideally. clearing agents or second antibody
should be administered at a time when the antibody has reached its
maximal value in the tumour so as to avoid excessive loss of
activity. However. [9°Y]A5B7 IgG accumulates in the tumour up to
72 h (refer to Figure 2A). by which time blood levels have
declined naturally and there would be little advantage in adminis-
tering a clearing agent at this time. In previous studies. clearing
agents have generally been administered 24-48 h after injection of
pnmarv antibody. which is usually at the approximate peak level
of tumour localization (Begent et al. 1987: Marshall et al. 1994).
These studies have also reported improved tumour-blood ratios.
It is. however. important to consider not only the biodistribution
data at various time points after clearance. but also area under the
curve analysis oftotal dose when considering the potential merit of
second antibody clearance. Although these dosimetry calculations
can only be considered as estimates. they have previously proved
useful predictors of toxicity and a guide to the levels of activitv
that may be administered for RIT (Pedley et al. 1989. 1993).
Surprisingly. although blood activity was significantly reduced
after second antibody administration this only had a small effect
on the cumulative radiation dose. most of which had already been
given before injection of second antibody (i.e. before 24 h). Thus.
these dosimetry estimates predicted no overall improvement in the
tumour-blood dose ratio. Without considering these calculations.
it would appear that the higher tumour-blood ratios observed at
specific time points after clearance from the biodistribution data
provide an advantage in terms of lower toxicitv.
The beneficial effect of second antibody clearance was observed
in the first 24 h after administration of clearing agent. when a
tenfold reduction in total dose to the blood occurred. However. this
was not reflected in the overall dose estimates because the
majority ofthe total dose to blood and tumour had occurred before
the clearing antibody was administered. Even at the earliest second
antibody clearance time point ( 18 h). the doses to blood and
tumour were reduced by a similar amount. which resulted in a
similar overall tumour-blood ratio. This indicates that there would
be no improvement in terms ofreduced toxicity on administration
of second antibody given at 18 h. 23 h or 47 h after injection of
[s8'Y]IgG. More accurate dosimetry evaluation. for example if the
data were fitted to an exponential clearance curve with more data
points and RIT experiments. would be required to confirm this
prediction.
If second antibody wAas administered at earlier time points after
injection of[`0Y]IgG. for example at 6 h. this would furtherreduce
the level ofradioactivity received during the first 24 h. although it
would be expected that there will also be a corresponding reduc-
tion in the dose level to the tumour. Previous studies have reported
that second antibody clearance at 6 h. both in nude mice bearinc
human colorectal tumour xenografts (Pedley et al.. 1989) and in
patients (Begent et al.. 1987). resulted in reduced activitv in the
tumour. although it exhibited the smallest reduction for any tissue.
These studies were performed using ''"I-labelled antibodies
compared with 9"Y used in this study. which may explain the
discrepancy. 90Y is a higher energy [emitter. which will deliver a
higher initial dose rate to the tumour than ''I. This results in the
relatively high absorbed dose during the first 24 h after administra-
tion. If the anti-macrocycle clearing antibodvsAas administered at
6 h. then it is possible that an improved cumulative tumour-blood
ratio could be generated. which may allow a larger amount of
activity to be administered. In addition. this will produce a higher
initial dose rate to the tumour which is known to be an important
parameter for successful RIT (Fowler. 1990). Furthermore. this
therapeutic strategy. which should ultimately reduce myelotoxicitv
by the early removal of radiolabelled primary antibody. would
favour repeated doses that could be administered at relatively
frequent intervals.
There are. however. two possible disadvantages to this thera-
peutic strategry. The immunogenicity of both murine antibodies
and the high levels ofadministered activity. and therefore protein.
required for therapy that may result in a large amount of immune
complex formation. which could saturate the reticuloendothelial
system and lead to the circulation of excess immune complexes.
Technoloay is now available to produce humanized antibodies.
and there is evidence to suggrest that the immune response for the
limited number of humanized antibodies used clinically so far is
largely reduced (Juweid et al.. 1995: Sharkey et al.. 1995:
Stephens et al.. 1995). The liver receives the highest normal tissue
absorbed dose with second antibody clearance. and. therefore.
careful attention to possible hepatic toxicity and clearance of
circulating immune complexes is required in a dose escalation
manner ifthis strategy is to be used cliically.
This clearance strategy is ofgreat interest because of its poten-
tial universal application to any anti-tumour antibody. Conjugation
ofthe 12N4 macrocycle is a mild procedure and does not generally
affect the immunoreactivit-v. This labelling procedure has also
been applied to cross-linked antibody fragments (Casey et al..
1996). If used in combination with a metallic isotope such as
indium- 111 and the anti-macrocycle antibody. this may be advan-
tageous for radioimmunodetection because improved images
could be generated at earlier time points.
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The purpose of giving second antibodv >-as to investigate
whether the radiation dose to bone marrow- could be reduced.
permitting a higher tumour dose to be delivered. Although blood
activity w-as sinificantlv reduced after second antibody adminis-
tration (given at 18. 23 or 47 h after primary antibodv). this onl1
had a small effect on the cumulative radiation dose. most of which
had been iyven before second antibody administration. If second
antibody was administered at an earlier time (e.g. 6 h after primary
antibod ). it is possible that the usefulness of this system could be
improved by the deliver- of a higher initial dose rate to the tumour
to achieve a oreater cell kill. Further experiments are required to
optimize this potentially new therapeutic strategy.
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